- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07945548
A Study Characterizing the Elevated Liver Enzymes in Ribociclib Treated HR+ HER2- Advanced Breast Cancer Patients Using a Machine Learning Approach With Real-world Data
Characterising the Elevated Liver Enzymes in Ribociclib (Kisqali®) Treatment Among Patients With HR+ HER2- Advanced Breast Cancer Using a Machine Learning Approach With Real-world Data
The aim of this study is to assess key factors associated with response and non-response to the current established management algorithm for elevated liver enzymes (ELE) following ribociclib treatment in hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (aBC) patients in real world settings in the United States (US). The data for this study will be drawn from a US-based breast cancer specific electronic health record (EHR) database.
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Novartis Pharmaceuticals
- Numero di telefono: +41613241111
- Email: novartis.email@novartis.com
Backup dei contatti dello studio
- Nome: Novartis Pharmaceuticals
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Adult patients in the US with a diagnosis of HR+/HER2- aBC and evidence of ribociclib use.
Descrizione
Inclusion criteria:
- Evidence of diagnosis of Stage IV breast cancer (aBC) as per American Joint Committee on Cancer (AJCC), 8th Edition during study period
- Aged 18 years or older at the index date
- Have at least one prescription for Ribociclib
- Have lab values available for alanine aminotransferase/aspartate aminotransferase (ALT/AST) at baseline, and up to 6 months post-baseline (at least one measurement at baseline and one measurement during follow up)
Exclusion criteria:
- Missing values for patient ID or age
- No available lab data for liver enzymes (ALT/AST) at either baseline or up to 6 months post-baseline
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: RETROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
|---|
|
Ribociclib Treatment Responders
Patients who undergo a management action (dose reduction or temporary suspension) and achieve recovery to ≤ baseline grade ALT/AST within 60 days without permanent treatment discontinuation or treatment switch. |
|
Ribociclib Treatment Non-responders
Patients who undergo a management action (dose reduction or temporary suspension) but whose ALT/AST level does not recover to baseline grade within 60 days, experience a worsening grade, recurrence after rechallenge, permanent treatment discontinuation or switch to another systemic therapy. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Number of Patients by Demographics and Clinical Characterisitcs
Lasso di tempo: Baseline
|
Demographics and clinical characteristics include age group, sex, race, ethnicity, geographical location, insurance type, socioeconomic status (SES) index (1 = lowest SES, 2, 3, 4, 5 = highest SES), menopausal status, smoking status, year of breast cancer (BC) diagnosis, type of BC, biomarker status, Eastern Cooperative Oncology (ECOG) performance status (0 = fully active, 1, 2, 3, 4 = completely disabled) number of metastatic sites, site of metastasis, chemotherapy status, radiation status, surgery status, and comorbidities. |
Baseline
|
|
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Age at Ribociclib Initiation
Lasso di tempo: Baseline
|
Baseline
|
|
|
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Duration of Follow-up
Lasso di tempo: Up to approximately 12 months
|
Up to approximately 12 months
|
|
|
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Body Weight
Lasso di tempo: Baseline
|
Baseline
|
|
|
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Charlson Comorbidity Index (CCI)
Lasso di tempo: Baseline
|
CCI is a weighted index that takes into account both the number and the seriousness of comorbid conditions. Each condition is assigned a weighted score, and the scores are summed to generate a total CCI score. Total scores range from 0 to 37, with higher scores reflecting a greater burden of disease and an increased risk of mortality. |
Baseline
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Number of Patients by Demographics and Clinical Characterisitcs
Lasso di tempo: Baseline
|
Demographics and clinical characteristics include age group, sex, race, ethnicity, geographical location, insurance type, SES index (1 = lowest SES, 2, 3, 4, 5 = highest SES), menopausal status, smoking status, year of BC diagnosis, type of BC, biomarker status, ECOG performance status (0 = fully active, 1, 2, 3, 4 = completely disabled) number of metastatic sites, site of metastasis, chemotherapy status, radiation status, surgery status, and comorbidities. |
Baseline
|
|
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Age at Ribociclib Initiation
Lasso di tempo: Baseline
|
Baseline
|
|
|
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Duration of Follow-up
Lasso di tempo: Up to approximately 12 months
|
Up to approximately 12 months
|
|
|
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Body Weight
Lasso di tempo: Baseline
|
Baseline
|
|
|
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, CCI
Lasso di tempo: Baseline
|
Baseline
|
|
|
Among aBC Patients Who Experience a First ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Number of Patients With Subsequent Episodes of ALT/AST Elevation
Lasso di tempo: Up to approximately 12 months
|
Up to approximately 12 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CLEE011A2010
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .